B Riley Likes Tocagen On Prospects For Company's Brain Cancer Drug
A little more than a year after its initial public offering, Tocagen Inc (NASDAQ: TOCA) has traded down 26 percent, but experts are decidedly bullish on the company’s prospects and potential valuation.
The Rating
B Riley analyst Madhu Kumar initiated coverage on Tocagen with a Buy rating and a $15 price target.
The Thesis
As Kumar sees it, Toca 511/FC has potential to transform the treatment of recurrent high-grade glioma (RHGG), a brain cancer affecting about 14,000 per year with limited-efficacy treatment options.
“Overall, RHGG remains a key clinical opportunity for novel therapies that can demonstrate improved therapeutic response,” Kumar wrote in a Wednesday note.
The failures of comparable candidates for RHGG, such as Vascular Biogenics Ltd (NASDAQ: VBLT)’s VB-111, have little read-across to Toca 511/FC, he said.
Given that Phase 1 data demonstrated positive enough results to merit Breakthrough Therapy Designation and PRIME Designation, Kumar anticipates success in Tocagen’s ongoing Phase 3 TOCA 5 trial.
Interim readouts due in the second half of 2018 and first half of 2019 are seen to propel the stock, with the latter milestone driving a key inflection point. The analyst assumes a 30-percent probability of launch with a 30-percent market share but notes improvements to the estimates could support a $90 share price.
Price Action
Tocagen shares traded up 3 percent to $9.74 at time of publication.
Related Links:
Ziopharm Oncology CEO Wants To Disrupt The CAR-T Supply Chain
DelMar Pharma CEO Sheds Light On Glioblastoma, And How Its Drug Could Help John McCain
Latest Ratings for TOCA
Date | Firm | Action | From | To |
---|---|---|---|---|
Sep 2019 | Citi | Downgrades | Buy | Neutral |
Sep 2019 | Chardan Capital | Downgrades | Buy | Neutral |
Sep 2019 | Evercore ISI Group | Downgrades | Outperform | In-Line |
View More Analyst Ratings for TOCA
View the Latest Analyst Ratings
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: B Riley Madhu KumarAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga